TerminatedPHASE4INTERVENTIONAL
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
- Sponsor:
- AstraZeneca
- Conditions:
- Diabetes Mellitus, Type 2, Kidney Function Tests
- Enrollment:
- 24
- Started:
- Jul 2017
NCT03152084